ASTHMA CONTROL EVALUATION (ACE): A BIOMARKER-BASED APPROACH TO IMPROVING ASTHMA

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者的研究机构。 生活在低收入、市中心社区的哮喘儿童和青少年是一个高危人群，其特征是哮喘相关的发病率和死亡率增加。有一个重要的需要，以找到改善长期哮喘控制在这一人群的策略。 呼出的一氧化氮（eNO）是支气管炎症的标志物，在哮喘不受控制的时期似乎增加，在哮喘药物治疗期间减少。公司最近开始销售测量eNO的设备，作为监测和加强哮喘控制的一种手段，但还没有随机临床试验解决这种监测是否改善哮喘结果的问题。 本研究的目的是确定与仅根据临床参数选择治疗相比，根据eNO测量结合临床参数选择哮喘治疗是否能改善哮喘控制。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Asthmatic children and adolescents living in low-income, inner-city communities are a high-risk population characterized by increased asthma-related morbidity and mortality. There is an important need to find strategies for improving long term asthma control in this population. Exhaled nitric oxide (eNO), a marker of bronchial inflammation, appears to be increased during periods of uncontrolled asthma and decreased during treatment with medicines for asthma. Companies have recently started to market equipment to measure eNO as a means of monitoring and enhancing asthma control, but no randomized clinical trial has yet addressed the question of whether such monitoring improves asthma outcomes. The purpose of this study is to determine whether selection of asthma therapy on the basis of eNO measurements combined with clinical parameters improves asthma control compared with therapy chosen solely on the basis of clinical parameters.